Immunopharmacology And Immunotoxicology

雜志介紹

Immunopharmacology And Immunotoxicology雜志介紹

《Immunopharmacology And Immunotoxicology》是一本以English為主的未開放獲取國際優秀期刊，中文名稱免疫藥理學和免疫毒理學，本刊主要出版、報道醫學-TOXICOLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為2.9，最新CiteScore 指數為5.4。

本刊近期中國學者發表的論文主要有：

• Xanthones from securidaca inappendiculata antagonizes the anti-rheumatic effect of methotrexate by inhibiting reduced folate carrier 1

  Author: Zhang, Sa-sa; Wu, Yi-jin; Pan, Shu; Wang, Qi-hai; Chen, Wen-gang; Wang, Zhong-fang; Xu, Jin-ying; Zuo, Jian; Yin, Qin

• A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

  Author: Liu, Tong; Jiang, Shuai; Teng, Xue; Zhong, Lu; Liu, Mengmeng; Jin, Yao; Dong, Mei

• Corynoline ameliorates dextran sulfate sodium-induced colitis in mice by modulating Nrf2/NF-kappa B pathway

  Author: Zhang, Haihua; Lang, Wuying; Li, Sufen; Xu, Chao; Wang, Xiumin; Li, Yunyu; Zhang, Zhiqiang; Wu, Tonglei; Feng, Minshan

• Sulforaphane suppresses skin squamous cell carcinoma cells proliferation through miR-199a-5p/Sirt1/CD44ICD signaling pathway

  Author: Zhang, Yang; Ai, Ping; Chen, Shang-zhou; Lei, Shu-ying

英文介紹

Immunopharmacology And Immunotoxicology雜志英文介紹

The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.

The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.

With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.

Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).